Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Sakthimala Jagadeesan
Massachusetts Eye and Ear Infirmary, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Genma Biosciences
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Jagadeesan’s spouse is an employee of Genma Biosciences, Inc., a privately held company focused on the utilization of a high throughput C. elegans screening platform to discover novel therapies and drug targets. The overall goal of the NIH grant identified above is to develop new approaches for treating and preventing multidrug resistant MRSA and VRE infection. The goal of subproject #2 under this grant is to use a C. elegans-MRSA infection model to identify novel anti-microbial compounds. Genma Biosciences is in the process of licensing C. elegans screening technology used in this research. It is also possible that Genma may have an interest in genes identified through this research. The Partners Committee on Outside Activities review panel evaluated Dr. Jagadeesan’s financial interest in connection with the research project and determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Harvard-wide Program on Antibiotic Resistance
Narrative Antibiotic resistance is a foremost public health concern worldwide. The Harvard-wide Program on Antibiotic Resistance, which has as its goal to develop new approaches for treating and preventing multidrug resistant MRSA and VRE infection, was specifically designed to be responsive to this global urgency. A highly productive multidisciplinary team will function collaboratively to capitalize on many advances it has already made to achieve this goal. � �
Filed on April 10, 2018.
Tell us what you know about Sakthimala Jagadeesan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.